For instance, biparatopic HER2-targeted BsAbs are able to retain high-affinity engagement even in heterogeneous tumours expressing a broad range of HER2, enabling more potent receptor internalization and effective inhibition of the signal pathways or payload deposition when combined with ADC payloads or used as single cytotoxic effects [104]. The gene discussed is ERBB2; the disease is neoplasm.